Transdermal Granisetron May Be Appropriate for CINV Prevention in Lung Cancer
Granisetron transdermal system may be appropriate for prevention of CINV in lung cancer.
ORLANDO, FL—A granisetron transdermal system (GTS) may be an appropriate option for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with lung cancer treated with highly emetic multiday chemotherapy, according to a study presented at the Oncology Nursing Society (ONS) 40th Annual Congress.
Chemotherapy for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) frequently requires platin-based regimens likely to cause emesis. Adherence to antiemetic regimens over several days is difficult for many patients, explained Doris Wong, BA, from Prostrakan Inc, Bridgewater, New Jersey.
A granisetron transdermal system has been shown to be as efficacious as oral granisetron in prevention of CINV, so researchers sought to conduct a retrospective analysis to assess the efficacy and safety of the transdermal formulation in difficult-to-treat patients with lung cancer.
Researchers analyzed data from a phase 3 study that compared transdermal granisetron to oral granisetron in 128 patients who received either moderately or highly emetogenic chemotherapy for 3 to 5 days.
An analysis of only patients with lung cancer showed no significant difference between GTS and oral granisetron in rates of complete control (no vomiting, mild nausea, no rescue), complete response (no vomiting, no rescue), the use of rescue medication, and patient assessment of response.
All treatment-related adverse events were mild; however, constipation was more frequent with GTS.
In regard to safety, transdermal granisetron was well tolerated and treatment-related side effects were mild in this patient population.